Coronary Calcium Score and Cardiovascular Risk

Who actually needs a statin? For a whole category of healthy, symptom-free adults, cholesterol numbers and risk calculators give no clean answer. This review makes the case that a single test answers the question better than anything else we have: the coronary artery calcium score.

Greenland and colleagues — among them the researchers who built the major cohort datasets in this field — synthesize evidence from population studies spanning the United States, Germany, and the Netherlands, with follow-up reaching fifteen years. Their conclusion is unusually direct for a review of this kind. In people without symptoms, the calcium score is the single most predictive marker of cardiovascular risk, adding information beyond every traditional risk factor combined.

What makes the score useful is that it sorts in both directions. A score of zero is not a small reassurance; it places ten-year risk near 1.4 percent and can justify holding off on a statin even in someone the guidelines would otherwise treat. At the other end, a score above 100 puts event rates in the range of established heart disease, and a score of 400 or more marks someone who stands to gain from intensive prevention. The number needed to treat tells the same story in plainer terms: roughly 124 people treated to prevent one event when calcium is absent, versus 19 when it is elevated — a six-fold difference that turns a blunt population strategy into a targeted one.

The same logic clarifies aspirin, a drug whose benefits and bleeding risks sit close to balance. At a calcium score of zero, the review finds net harm; above 100, net benefit — a cleaner decision rule than most patients are ever offered. And the score appears to change behavior, not just classification: in a randomized trial, people who saw their own calcium results improved their risk factors more than those who did not.

The evidence here is strong, and we rate it accordingly. The honest limit is that calcium-guided care has not been tested head-to-head against standard care in a trial measuring hard outcomes, and major guidelines still list the score as a secondary consideration. But for the specific, common problem of deciding whether an asymptomatic person should begin lifelong therapy, few tests offer this much clarity.